瑞士两大药业巨人汽巴—嘉基制药和圣多兹公司合并,组成世界第二大药业公司的诺华制药,堪称国际药业的一次大地震,毕竟,270亿规模的合并案在这个行业历史上尚无先例。但一加一大于二的梦想并未成真。自1996年末出炉以来,诺华市场表现相当庸常,目前销售额在世界同行中仅排在第七位,产量增加速度和利润都大大低于瑞辉药业等竞争对手。诺华总裁兼 CEO 丹尼尔·瓦塞尔拉一开始就认识到,在这次制药产业的最大合并交易中,自己也接过了难以下咽的佐料——两个公司原有的积重难返的弊 Novartis, the world’s second-largest drug company, merged with Switzerland’s two largest pharmaceutical giants Ciba-Geigy and Santos, a massive earthquake in the international pharmaceutical industry. After all, 27 billion mergers There is no precedent in this industry history. But the dream of one plus one more than two did not come true. Since its launch in late 1996, Novartis has performed fairly well, with sales now ranking only the seventh in the world in terms of both volume and profitability, compared with rivals such as Ruihui. Novartis President and CEO Daniel Vassella realized from the outset that herself had taken over the hard-to-swallow upstairs in the largest merger of the pharmaceutical industry - the two companies’